Mezigdomide
Peripheral T Cell Lymphoma
CellCentric Ltd.Small moleculePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 73/ 100
Competitive context
52 Active assets in the Peripheral T Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tucidinostat Ruijin Hospital | Phase 4 | BB |
shr2554 Sun Yat-sen University | Phase 3 | BB |
DEXAMETHASONE Ou Bai, MD/PHD | Phase 4 | BB |
Ifosfamide New York Medical College | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Ou Bai, MD/PHD | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Mezigdomide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →